Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Disclosure
Abbreviations
UTUC | Upper Tract Urothelial Carcinoma |
UC | Urothelial Carcinoma |
BC | Bladder Cancer |
KPP | Kidney Preserving Procedures |
PFS | Progression free survival |
fURS | Flexible Ureteroscopy |
Ho:YAG | Holmium:YAG |
References
- Soria, F.; Shariat, S.F.; Lerner, S.P.; Fritsche, H.-M.; Rink, M.; Kassouf, W.; Spiess, P.E.; Lotan, Y.; Ye, D.; Fernandez, M.I.; et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J. Urol. 2016, 35, 379–387. [Google Scholar] [CrossRef]
- Olgac, S.; Mazumdar, M.; Dalbagni, G.; Reuter, V.E. Urothelial Carcinoma of the Renal Pelvis: A clinicopathologic study of 130 cases. Am. J. Surg. Pathol. 2004, 28, 1545–1552. [Google Scholar] [CrossRef] [PubMed]
- Hall, M.; Womack, S.; Sagalowsky, A.I.; Carmody, T.; Erickstad, M.D.; Roehrborn, C.G. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients. Urology 1998, 52, 594–601. [Google Scholar] [CrossRef]
- Elawdy, M.M.; Osman, Y.; Taha, D.E.; El-Halwagy, S.; El-Hamid, M.A.; Abouelkheir, R.T. Long-term outcomes of upper tract urothelial carcinoma: A retrospective evaluation of single-center experience in 275 patients. Turk. J. Urol. 2019, 45, 177–182. [Google Scholar] [CrossRef]
- Rouprêt, M.; Babjuk, M.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Cowan, N.C.; Dominguez-Escrig, J.L.; Gontero, P.; Mostafid, A.H.; et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur. Urol. 2020, 79, 62–79. [Google Scholar] [CrossRef] [PubMed]
- Hasan, M.N.; Rouprêt, M.; Keeley, F.; Cracco, C.; Jones, R.; Straub, M.; Traxer, O.; Osther, P.J.S.; Brehmer, M. Consultation on UTUC, Stockholm 2018 aspects of risk stratification: Long-term results and follow-up. World J. Urol. 2019, 37, 2289–2296. [Google Scholar] [CrossRef] [PubMed]
- Bianconi, M.; Cimadamore, A.; Faloppi, L.; Scartozzi, M.; Santoni, M.; López-Beltrán, A.; Cheng, L.; Scarpelli, M.; Montironi, R. Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Ther. Adv. Urol. 2019, 11, 1756287218815372. [Google Scholar] [CrossRef]
- Mandalapu, R.S.; Remzi, M.; De Reijke, T.M.; Margulis, V.; Palou, J.; Kapoor, A.; Yossepowitch, O.; Coleman, J.; Traxer, O.; Anderson, J.K.; et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: Treatment of low-risk upper tract urothelial carcinoma. World J. Urol. 2016, 35, 355–365. [Google Scholar] [CrossRef]
- Fiuk, J.V.; Schwartz, B.F. Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management. World J. Nephrol. 2016, 5, 158–165. [Google Scholar] [CrossRef]
- Roupret, M.; Colin, P.; Yates, D.R. A new proposal to risk stratify urothelial carcinomas of the upper urinary tract (UTUCs) in a predefinitive treatment setting: Low-risk versus high-risk UTUCs. Eur. Urol. 2014, 66, 181–183. [Google Scholar] [CrossRef]
- Seisen, T.; Colin, P.; Rouprêt, M. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat. Rev. Urol. 2015, 12, 155–166. [Google Scholar] [CrossRef]
- Rouprêt, M.; Hupertan, V.; Traxer, O.; Loison, G.; Chartier-Kastler, E.; Conort, P.; Bitker, M.-O.; Gattegno, B.; Richard, F.; Cussenot, O. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 2006, 67, 1181–1187. [Google Scholar] [CrossRef]
- Colin, P.; Rouprêt, M.; Ghoneim, T.P.; Traxer, O.; Zerbib, M.; Xylinas, E. Conservative Management of Upper Tract Urothelial Carcinoma in France: A 2004–2011 National Practice Report. Eur. Urol. 2013, 63, 405–406. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.L.; Bagley, D.H. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal con-tralateral kidneys. J. Urol. 2000, 164, 1173–1176. [Google Scholar] [CrossRef]
- Emiliani, E.; Talso, M.; Haddad, M.; Pouliquen, C.; Derman, J.; Côté, J.-F.; Doizi, S.; Millán, F.; Berthe, L.; Audouin, M.; et al. The True Ablation Effect of Holmium YAG Laser on Soft Tissue. J. Endourol. 2018, 32, 230–235. [Google Scholar] [CrossRef]
- Proietti, S.; Rodríguez-Socarrás, M.E.; Eisner, B.H.; Lucianò, R.; Martinez, M.J.B.; Yeow, Y.; Rapallo, I.; Saitta, G.; Scarfò, F.; Gaboardi, F.; et al. Thulium:YAG Versus Holmium:YAG Laser Effect on Upper Urinary Tract Soft Tissue: Evidence from an Ex Vivo Experimental Study. J. Endourol. 2021, 35, 544–551. [Google Scholar] [CrossRef]
- Doizi, S.; Germain, T.; Panthier, F.; Comperat, E.; Traxer, O.; Berthe, L. Comparison of Holmium:YAG and Thulium Fiber lasers on soft tissue: An ex vivo study. J. Endourol. 2021. [Google Scholar] [CrossRef]
- Rouprêt, M.; Babjuk, M.; Compérat, E.; Zigeuner, R.; Sylvester, R.J.; Burger, M.; Cowan, N.C.; Gontero, P.; Van Rhijn, B.W.; Mostafid, A.H.; et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur. Urol. 2018, 73, 111–122. [Google Scholar] [CrossRef]
- Roupręt, M.; Xylinas, E.; Colin, P.; Houédé, N.; Compérat, E.; Audenet, F.; Larré, S.; Masson-Lecomte, A.; Pignot, G.; Brunelle, S.; et al. Recommandations françaises du Comité de Cancérologie de l’AFU–Actualisation 2018–2020: Tumeurs de la voie excrétrice supérieure. Prog. Urol. 2018, 28, S32–S35. [Google Scholar] [CrossRef] [PubMed]
- Rouprêt, M.; Babjuk, M.; Compérat, E.; Zigeuner, R.; Sylvester, R.J.; Burger, M.; Cowan, N.C.; Böhle, A.; Van Rhijn, B.W.; Kaasinen, E.; et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur. Urol. 2015, 68, 868–879. [Google Scholar] [CrossRef]
- Rouprêt, M.; Babjuk, M.; Compérat, E.; Zigeuner, R.; Sylvester, R.; Burger, M.; Cowan, N.; Böhle, A.; Van Rhijn, B.W.; Kaasinen, E.; et al. European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. Eur. Urol. 2013, 63, 1059–1071. [Google Scholar] [CrossRef]
- Huusmann, S.; Wolters, M.; Kramer, M.W.; Bach, T.; Teichmann, H.O.; Eing, A.; Bardosi, S.; Herrmann, T.R. Tissue damage by laser radiation: An in vitro comparison between Tm: YAG and Ho: YAG laser on porcine kidney model. Singerplus 2016, 5, 266. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Taratkin, M.; Kovalenko, A.; Laukhtina, E.; Paramonova, N.; Spivak, L.; Wachtendorf, L.J.; Eminovic, S.; Afyouni, A.S.; Okhunov, Z.; Karagezyan, M.; et al. Ex vivo study of Ho:YAG and Thulium fiber lasers for soft tissue surgery: Wich laser for which case? Lasers Med. Sci. 2020, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Verges, D.P.; Lallas, C.D.; Hubosky, S.G.; Bagley, D.H. Endoscopic Treatment of Upper Tract Urothelial Carcinoma. Curr. Urol. Rep. 2017, 18, 31. [Google Scholar] [CrossRef] [PubMed]
- Azémar, M.-D.; Comperat, E.; Richard, F.; Cussenot, O.; Rouprêt, M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. Urol. Oncol. Semin. Orig. Investig. 2011, 29, 130–136. [Google Scholar] [CrossRef] [PubMed]
- Margulis, V.; Shariat, S.F.; Matin, S.F.; Kamat, A.M.; Zigeuner, R.; Kikuchi, E.; Lotan, Y.; Weizer, A.; Raman, J.; Wood, C.G.; et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009, 115, 1224–1233. [Google Scholar] [CrossRef]
- Leow, J.J.; Orsola, A.; Chang, S.L.; Bellmunt, J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat. Rev. 2015, 41, 310–319. [Google Scholar] [CrossRef]
- Lughezzani, G.; Burger, M.; Margulis, V.; Matin, S.F.; Novara, G.; Roupret, M.; Shariat, S.F.; Wood, C.G.; Zigeuner, R. Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. Eur. Urol. 2012, 62, 100–114. [Google Scholar] [CrossRef]
- Seisen, T.; Peyronnet, B.; Dominguez-Escrig, J.L.; Bruins, H.M.; Yuan, C.Y.; Babjuk, M.; Böhle, A.; Burger, M.; Compérat, E.M.; Cowan, N.C.; et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur. Urol. 2016, 70, 1052–1068. [Google Scholar] [CrossRef]
- Yates, D.R.; Hupertan, V.; Colin, P.; Ouzzane, A.; Descazeaud, A.; Long, J.A.; Pignot, G.; Crouzet, S.; Rozet, F.; Neuzillet, Y.; et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: Proposal and multi-institutional validation of a post-operative nomogram. Br. J. Cancer 2012, 106, 1083–1088. [Google Scholar] [CrossRef]
- Cutress, M.L.; Stewart, G.D.; Wells-Cole, S.; Phipps, S.; Thomas, B.G.; Tolley, D.A. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. 2012, 110, 1608–1617. [Google Scholar] [CrossRef]
- Cornu, J.-N.; Rouprêt, M.; Carpentier, X.; Geavlete, B.; Medina, S.G.D.D.; Cussenot, O.; Traxer, O. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J. Urol. 2010, 28, 151–156. [Google Scholar] [CrossRef] [PubMed]
- Soderdahl, D.W.; Fabrizio, M.D.; Rahman, N.U.; Jarrett, T.W.; Bagley, D.H. Endoscopic treatment of upper tract transitional cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 2005, 23, 114–122. [Google Scholar] [CrossRef] [PubMed]
- Pieras, E.; Frontera, G.; Ruiz, X.; Vicens, A.; Ozonas, M.; Pizá, P. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int. 2010, 106, 1319–1323. [Google Scholar] [CrossRef] [PubMed]
- Simone, G.; Papalia, R.; Loreto, A.; Leonardo, C.; Sentinelli, S.; Gallucci, M. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 2009, 103, 1052–1057. [Google Scholar] [CrossRef] [PubMed]
- Villa, L.; Haddad, M.; Capitanio, U.; Somani, B.; Cloutier, J.; Doizi, S.; Salonia, A.; Briganti, A.; Montorsi, F.; Traxer, O. Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution. J. Urol. 2017, 199, 66–73. [Google Scholar] [CrossRef]
- Scotland, K.B.; Kleinmann, N.; Cason, D.; Hubbard, L.; Tanimoto, R.; Healy, K.A.; Hubosky, S.G.; Bagley, D.H. Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience. Urology 2018, 121, 66–73. [Google Scholar] [CrossRef]
- Finch, W.; Johnston, R.; Shaida, N.; Winterbottom, A.; Wiseman, O. Measuring stone volume-three-dimensional software reconstruction or an ellipsoid algebra formula? BJU Int. 2014, 113, 610–614. [Google Scholar] [CrossRef]
- Panthier, F.; Doizi, S.; Illoul, L.; Berthe, L.; Traxer, O. Developing Free Three-dimensional Software for Surgical Planning for Kidney Stones: Volume is Better than Diameter. Eur. Urol. Focus 2020, 7, 589–590. [Google Scholar] [CrossRef] [PubMed]
- Mazzucchelli, R.; Scarpelli, M.; Galosi, A.B.; Di Primio, R.; Lopez-Beltran, A.; Cheng, L.; Montironi, R. Pathology of upper tract urothelial carcinoma with emphasis on staging. Int. J. Immunopathol. Pharmacol. 2014, 27, 509–516. [Google Scholar] [CrossRef]
- Aldoukhi, A.H.; Hall, T.L.; Ghani, K.R.; Maxwell, A.D.; MacConaghy, B.; Roberts, W.W. Caliceal Fluid Temperature During High-Power Holmium Laser Lithotripsy in an In Vivo Porcine Model. J. Endourol. 2018, 32, 724–729. [Google Scholar] [CrossRef] [PubMed]
- Musi, G.; Mistretta, F.A.; Marenghi, C.; Russo, A.; Catellani, M.; Nazzani, S.; Conti, A.; Luzzago, S.; Ferro, M.; Matei, D.V.; et al. Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. J. Endourol. 2018, 32, 257–263. [Google Scholar] [CrossRef] [PubMed]
Group | Time (min) to Complete Ablation. Mean (SD) | Percentage of Non-Affected Tissue | Percentage of Ablated Necrotic Tissue with Recognizable Architecture | Percentage of Destroyed Unrecognized Tissue |
---|---|---|---|---|
1 (1 cm3) | 16.4 (2.7) | 0% | 0% | 100% |
2 (1.5 cm3) | 28.1 (2.5) | 0% | 0% | 100% |
3 (2 cm3) | 40.3 (3.3) | 0% | 0% | 100% |
4 (2.5 cm3) | 53.7 (4.3) | 0% | 8% | 92% |
5 (3 cm3) | 69.7 (6.6) | 0% | 15% | 85% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barghouthy, Y.; Corrales, M.; Sierra, A.; Kamkoum, H.; Capretti, C.; Somani, B.; Compérat, E.; Traxer, O. Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation. Uro 2022, 2, 13-20. https://doi.org/10.3390/uro2010003
Barghouthy Y, Corrales M, Sierra A, Kamkoum H, Capretti C, Somani B, Compérat E, Traxer O. Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation. Uro. 2022; 2(1):13-20. https://doi.org/10.3390/uro2010003
Chicago/Turabian StyleBarghouthy, Yazeed, Mariela Corrales, Alba Sierra, Hatem Kamkoum, Camilla Capretti, Bhaskar Somani, Eva Compérat, and Olivier Traxer. 2022. "Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation" Uro 2, no. 1: 13-20. https://doi.org/10.3390/uro2010003
APA StyleBarghouthy, Y., Corrales, M., Sierra, A., Kamkoum, H., Capretti, C., Somani, B., Compérat, E., & Traxer, O. (2022). Endoscopic Treatment of Upper Tract Urothelial Carcinoma: Challenging the Definition of the Maximal Lesion Size for Safe Ablation. Uro, 2(1), 13-20. https://doi.org/10.3390/uro2010003